{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:46:35Z","timestamp":1793677595398,"version":"4.5.1"},"reference-count":42,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013302","name":"King Abdullah International Medical Research Center","doi-asserted-by":"publisher","award":["RSS19.037.R"],"award-info":[{"award-number":["RSS19.037.R"]}],"id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objective: Cisplatin is a chemotherapy drug used to treat several types of malignancies. It is a platinum-based compound that interferes with cell division and DNA replication. Cisplatin has been associated with renal damage. This study evaluates the early detection of nephrotoxicity through routine laboratory tests. Materials and Methods: This is a retrospective chart review based on the Saudi Ministry of National Guard Hospital (MNGHA). We evaluated deferential laboratory tests for cancer patients treated with cisplatin between April 2015 and July 2019. The evaluation included age, sex, WBC, platelets, electrolytes, co-morbidities and interaction with radiology. Results: The review qualified 254 patients for evaluation. Around 29 patients (11.5%) had developed kidney function abnormality. These patients presented with abnormally low magnesium 9 (31%), potassium 6 (20.7%), sodium 19 (65.5%) and calcium 20 (69%). Interestingly, the whole sample size had abnormal electrolytes presenting magnesium 78 (30.8%), potassium 30 (11.9%), sodium 147 (58.1%) and calcium 106 (41.9%). Some pathological features were detected, such as hypomagnesemia, hypocalcemia and hypokalemia. In addition, infections that needed antibiotics were dominant in patients treated with cisplatin alone, representing 50% of this group. Conclusions: We report that an average of 15% of patients with electrolyte abnormalities develop renal toxicity and reduced function. Moreover, electrolytes may serve as an early indicator for renal damage as part of chemotherapy complication. This indication represents 15% of renal toxicity cases. Changes in electrolyte levels have been reported with cisplatin. Specifically, it has been linked to hypomagnesemia, hypocalcemia and hypokalemia. This study will help reduce the risk of dialysis or the need for kidney transplant. It is also important to manage any underlying conditions and control patients\u2019 intake of electrolytes.<\/jats:p>","DOI":"10.3390\/medicina59050890","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T04:04:48Z","timestamp":1683518688000},"page":"890","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Electrolytes Play a Role in Detecting Cisplatin-Induced Kidney Complications and May Even Prevent Them\u2014Retrospective Analysis"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-9187","authenticated-orcid":false,"given":"Bahauddeen M.","family":"Alrfaei","sequence":"first","affiliation":[{"name":"Cellular Therapy and Cancer Research Department, King Abdullah International Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences, Riyadh 14611, Saudi Arabia"},{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh 14611, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz O.","family":"Almutairi","sequence":"additional","affiliation":[{"name":"College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh 14611, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa A.","family":"Aljohani","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh 14611, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajar","family":"Alammar","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh 14611, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6304-2943","authenticated-orcid":false,"given":"Abdulaziz","family":"Asiri","sequence":"additional","affiliation":[{"name":"Faculty of Applied Medical Sciences, University of Bisha, 255, Al Nakhil, Bisha 67714, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Bokhari","sequence":"additional","affiliation":[{"name":"Department of AI and Bioinformatics, King Abdullah International Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi Arabia"},{"name":"Department of Health Informatics, College of Public Health and Health Informatics, King Saud bin Abdulaziz University for Health Sciences, Riyadh 11426, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feda S.","family":"Aljaser","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 12371, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3578-8988","authenticated-orcid":false,"given":"Manal","family":"Abudawood","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 12371, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Halwani","sequence":"additional","affiliation":[{"name":"Nanomedicine Department, King Abdullah International Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5049\/EBP.2014.12.2.55","article-title":"Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies","volume":"12","author":"Oh","year":"2014","journal-title":"Electrolyte Blood Press."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Phung, H.M., Lee, S., Hwang, J.H., and Kang, K.S. (2020). Preventive effect of muscone against cisplatin nephrotoxicity in llc-pk1 cells. Biomolecules, 10.","DOI":"10.3390\/biom10101444"},{"key":"ref_4","first-page":"753","article-title":"Analysis of cisplatin-induced ototoxicity risk factors in iranian patients with solid tumors: A cohort, prospective and single institute study","volume":"18","author":"Khosravi","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/annonc\/mdf048","article-title":"Long-term renal function after treatment for malignant germ-cell tumours","volume":"13","author":"Aass","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00001813-200602000-00013","article-title":"Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer","volume":"17","author":"Shord","year":"2006","journal-title":"Anti-Cancer Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3109\/10408444.2011.602662","article-title":"An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity","volume":"41","author":"Morales","year":"2011","journal-title":"Crit. Rev. Toxicol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.radonc.2012.08.022","article-title":"Increased treatment-related mortality with additional cisplatin-based chemotherapy in patients with nasopharyngeal carcinoma treated with standard radiotherapy","volume":"104","author":"Zhang","year":"2012","journal-title":"Radiother. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/sj.bjc.6605860","article-title":"Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (tpf), 5-fluorouracil (pf) for induction in unresectable locoregionally advanced head and neck cancer patients (eortc 24971\/tax 323)","volume":"103","author":"Mauer","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-18-3179","article-title":"Clinical and genome-wide analysis of cisplatin-induced tinnitus implicates novel ototoxic mechanisms","volume":"25","author":"Mapes","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_11","unstructured":"Brock, P., Rajput, K., Edwards, L., Meijer, A., Simpkin, P., Hoetink, A., Kruger, M., Sullivan, M., and van den Heuvel-Eibrink, M. (2021). Hearing Loss-From Multidisciplinary Teamwork to Public Health, IntechOpen."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/cam4.1563","article-title":"Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials","volume":"7","author":"Minasian","year":"2018","journal-title":"Cancer Med."},{"key":"ref_13","first-page":"1","article-title":"Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine","volume":"11","author":"Veerman","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(20)30540-7","article-title":"The link between kidney disease and cancer: Complications and treatment","volume":"396","author":"Malyszko","year":"2020","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/ajrimps\/2019\/v7i430126","article-title":"Biochemical and molecular studies on the role of rosemary (Rosmarinus officinalis) extract in reducing liver and kidney toxicity due to etoposide in male rats","volume":"5","author":"Almakhatreh","year":"2019","journal-title":"Asian J. Res. Med. Pharm. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/bs.acr.2021.03.008","article-title":"Cisplatin chemotherapy and renal function","volume":"152","author":"Zhang","year":"2021","journal-title":"Adv. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00228-019-02771-5","article-title":"Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity","volume":"76","author":"Casanova","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/ctrv.1999.0097","article-title":"Cisplatin and hypomagnesemia","volume":"25","author":"Lajer","year":"1999","journal-title":"Cancer Treat. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.1993.1184","article-title":"Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin","volume":"50","author":"Cornelison","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","article-title":"Cisplatin nephrotoxicity: A review of the literature","volume":"31","author":"Manohar","year":"2018","journal-title":"J. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0272-6386(86)80020-8","article-title":"Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin","volume":"8","author":"Lam","year":"1986","journal-title":"Am. J. Kidney Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/0003-4819-95-5-628","article-title":"Renal and electrolyte disturbances associated with cisplatin","volume":"95","author":"Blachley","year":"1981","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/SMJ.0b013e3181e63682","article-title":"Cisplatin-induced renal salt wasting syndrome","volume":"103","author":"Hamdi","year":"2010","journal-title":"South Med. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","article-title":"Cisplatin nephrotoxicity: A review","volume":"334","author":"Yao","year":"2007","journal-title":"Am. J. Med. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Loren, P., Saavedra, N., Saavedra, K., Zambrano, T., Moriel, P., and Salazar, L.A. (2021). Epigenetic mechanisms involved in cisplatin-induced nephrotoxicity: An update. Pharmaceuticals, 14.","DOI":"10.3390\/ph14060491"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"F505","DOI":"10.1152\/ajprenal.90545.2008","article-title":"The copper transporter ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity","volume":"296","author":"Pabla","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_28","first-page":"396","article-title":"Contribution of organic cation transporter 2 (oct2) to cisplatin-induced nephrotoxicity","volume":"86","author":"Filipski","year":"2009","journal-title":"Clin Pharm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00701-005-0659-3","article-title":"Diagnostic mr imaging features of craniocerebral aspergillosis of sino-nasal origin in immunocompetent patients","volume":"148","author":"Siddiqui","year":"2006","journal-title":"Acta Neurochir."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.ASN.0000042803.28024.92","article-title":"Metabolism of cisplatin to a nephrotoxin in proximal tubule cells","volume":"14","author":"Townsend","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1254\/jphs.FP0050661","article-title":"Relationship of intracellular calcium and oxygen radicals to cisplatin-related renal cell injury","volume":"100","author":"Kawai","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.bcp.2010.04.035","article-title":"Potential therapeutic implications of cancer stem cells in glioblastoma","volume":"80","author":"Cheng","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13046-017-0636-8","article-title":"Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through nf-\u03bab-tnf\u03b1-pik3ca loop","volume":"36","author":"Thakur","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A systematic review of strategies to prevent cisplatin-induced nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/COC.0000000000000301","article-title":"Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy","volume":"41","author":"Faig","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Minzi, O., Lyimo, T.E., Furia, F.F., Marealle, A.I., Kilonzi, M., Bwire, G.M., and Malichewe, C. (2020). Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-00448-9"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12929-019-0518-9","article-title":"Molecular mechanisms of cisplatin-induced nephrotoxicity: A balance on the knife edge between renoprotection and tumor toxicity","volume":"26","author":"Volarevic","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2353\/ajpath.2010.090610","article-title":"Organic cation transporter 2 mediates cisplatin-induced oto-and nephrotoxicity and is a target for protective interventions","volume":"176","author":"Ciarimboli","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_39","first-page":"57","article-title":"Prevention of cisplatin nephrotoxicity","volume":"5","author":"Hayati","year":"2016","journal-title":"J. Nephropharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1056\/NEJMoa1801109","article-title":"Sodium thiosulfate for protection from cisplatin-induced hearing loss","volume":"378","author":"Brock","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00210-018-1514-4","article-title":"Protective effects of amifostine, curcumin, and melatonin against cisplatin-induced acute kidney injury","volume":"391","author":"Mercantepe","year":"2018","journal-title":"Naunyn Schmiedebergs Arch Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","article-title":"Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer","volume":"14","author":"Kemp","year":"1996","journal-title":"J. Clin. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/5\/890\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:30:10Z","timestamp":1760124610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/5\/890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["medicina59050890"],"URL":"https:\/\/doi.org\/10.3390\/medicina59050890","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,6]]}}}